Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Peter Singleton who wrote (2926)	11/21/1997 6:11:00 PM
From: Oliver & Co	Respond to of 6136

A trial is a trial, is a trial. If they want FDA approval, they have to compare to the present "Gold Standard". Remember, that these people move very slowly. One big ethical question for researchers must be, what do they do? there are no good animal models, and they can not use humans as rats, but how do you get answers? I do not know. For me it is easy, I give patients the best> JLL

To: Peter Singleton who wrote (2926)	11/21/1997 7:17:00 PM
From: Izzy	Read Replies (1) \| Respond to of 6136

Peter: If I am not mistaken, Glaxo has partnerships in the development/manufacture of AZT (zidovudine),3TC (lamivudine), and 141W94 (VX-478, a 2nd generation HIV protease inhibitor).On 10-13-97, Vertex gave a newswire release regarding Phase III clinical trials in Belgium; not USA (VRTX stated it was going to try to enroll 1000 patients in Phase II, III trials in the USA). I do not find that AZT & 3TC were used alone as a comparison, but it wouldn't surprise me if that were not the case. I do not participate in clinical trials, so I cannot give you the mentality of those involved. However, it would appear to me to be unconscionable to use known ineffective treatments.